Pascal Soriot

26 results

 AstraZeneca’s wave of new medicines include Imfinzi and Tagrisso for lung cancer, Lynparza for ovarian cancer and Fasenra for severe asthma. Photograph: Stefan Wermuth//Reuters

Strong demand for AstraZeneca’s new drugs – especially those for cancer – drove a return to sales growth in the third quarter and the drugmaker said i(...)

Workers at  AstraZeneca’s  Macclesfield site in England.  Shares in the British drug giant suffered their largest ever fall as it announced a big setback, with a much-awaited trial of a new lung cancer drug failing to show the benefits for which the company had hoped. Photograph: Phil Noble/Reuters

Shares in AstraZeneca were on track to suffer their worst ever fall after the Anglo-Swedish pharmaceutical company suffered a big setback with a much-(...)

GlaxoSmithKline building in Hounslow, west London: GSK, one of Britain’s two Big Pharma firms, decided to abandon plans for a new manufacturing plant in Ulverston in Cumbria. Photograph: Luke MacGregor GlaxoSmithKline building in Hounslow, west London: GSK, one of Britain’s two Big Pharma firms, decided to abandon plans for a new manufacturing plant in Ulverston in Cumbria. Photograph: Luke MacGregor

In a week when the UK’s Eurosceptic international trade minister Liam Fox suggested the British economy could easily manage without a trade deal with (...)

Emma Walmsley will be paid an annual base salary of about £1 million

Emma Walmsley, poised to take over as the first female chief executive of GlaxoSmithKline, will earn about a quarter less than her predecessor Andrew (...)

AstraZeneca’s third-quarter sales were hit by competition from multiple generic versions of its cholesterol fighter Crestor. Photograph: Luke MacGregor/Reuters

Pharmaceutical giant AstraZeneca expects major US healthcare changes after Donald Trump’s election victory but its chief executive warned on Thursday (...)

GSK plans to increase production of next-generation respiratory drugs and biotech medicines.

GlaxoSmithKline plans £275 million of new investments at three drug manufacturing sites in Britain, signalling its confidence in the country despite (...)

Chief executive Pascal Soriot said AstraZeneca faced a “transitional period” due to the expiry of Crestor’s US patent in May, but the company was poised for a comeback and it would continue to plough investment into drug research

AstraZeneca warned on Thursday that revenue and earnings would drop this year due to the arrival of cheap generic rivals to Crestor, its top-selling c(...)

AstraZeneca agreed to buy a 55 per cent stake in Acerta Pharma for $4 billion to gain a potential blockbuster cancer medicine.

AstraZeneca agreed to buy a 55 per cent stake in Acerta Pharma for $4 billion to gain a potential blockbuster cancer medicine. The UK’s second-large(...)

AstraZeneca chief executive Pascal Soriot: ‘This acquisition complements our strategic focus on cardiovascular and metabolic disease.’ Photograph: Simon Dawson/Bloomberg

Britain’s AstraZeneca has agreed to buy US biotech company ZS Pharma for $2.7 billion, pipping Swiss firm Actelion to the prize in the latest bout of (...)

Bottles of AstraZeneca’s Nexium heartburn medication. Photographer: Daniel Acker/Bloomberg

AstraZeneca, the second-largest UK drug maker, said fourth-quarter earnings fell 33 per cent as revenue declined for two of its best-selling drugs and(...)

  • 1
  • 2
  • 3
  • Next
  • Last »